Vinorelbine plus everolimus versus vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial vicTORia.

18. Oktober 2018

Decker, T., Marschner, N., Welt, A., Riedt, T., Hagen, V., Rauh, J., Klein, D., Potthoff, K., Jähnig, P., Schröder, H., Lerchenmüller, C., 2018.

Oncol Res Treat 41 (suppl4)(V491), 158–159.